- Home
- Therapeutics Development Services
- PARP Peptide Inhibitor Development Services
Poly(ADP-ribose) polymerase (PARP) enzymes play a crucial role in a wide range of cellular processes, including DNA repair, gene expression, and cell signaling. As a leading preclinical contract research organization (CRO), Alfa Cytology provides PARP peptide inhibitor development services for combating various diseases.
In recent years, small molecule PARP inhibitors (PARPi) have emerged as a promising class of therapeutics, particularly in the field of oncology. However, the versatility of PARP-targeted therapies extends far beyond cancer, with growing interest in the potential of PARP peptide inhibitors to address a diverse array of diseases. Unlike their small molecule counterparts, PARP peptide inhibitors offer the potential for greater specificity, improved pharmacokinetic profiles, and reduced off-target effects.
Fig. 1 Design of PARP peptide inhibitor. (Pan C., et al. 2022)
By targeting the protein-protein interactions that govern PARP enzyme activity, these peptide-based inhibitors can selectively disrupt the critical pathways involved in disease pathogenesis, potentially leading to more effective and better-tolerated therapies.
At Alfa Cytology, we have established a comprehensive suite of services dedicated to the development of PARP peptide inhibitors. Our team of experts leverages their extensive knowledge and state-of-the-art capabilities to guide our clients through every step of the drug discovery process.
Peptide Design
Our seasoned team of biochemists and computational biologists collaborate to rationally design novel peptide sequences that can effectively bind and inhibit PARP enzymes. Through iterative rounds of structural modeling, site-directed mutagenesis, and in-depth biophysical characterization, we refine the lead peptide candidates to enhance their potency, selectivity, and drug-like properties.
Preclinical Efficacy Evaluation
Leveraging our state-of-the-art in vitro and in vivo models, we rigorously evaluate the therapeutic potential of PARP peptide inhibitor candidates across a range of disease indications. Our team expertly designs and executes targeted studies to assess the efficacy of these peptide-based therapeutics in relevant disease models, providing our clients with robust data to support the advancement of their drug development programs.
PK and Safety Assessment
Ensuring the favorable pharmacokinetic profile and safety of PARP peptide inhibitor candidates is a critical aspect of our preclinical services. We employ advanced analytical techniques, including ADME (absorption, distribution, metabolism, and excretion) studies and comprehensive toxicology evaluations, to thoroughly characterize the behavior and safety of these peptide-based therapeutics.
At Alfa Cytology, we are committed to empowering our clients' drug discovery efforts by providing unparalleled expertise and state-of-the-art capabilities in the development of PARP peptide inhibitors. Our team of biological experts stands ready to collaborate with you, leveraging our deep understanding of PARP biology and our proven track record in peptide-based drug development to accelerate your path to transformative therapies. To discuss potential collaborative opportunities, please don't hesitate to contact us.
Reference
For research use only. Not intended for any clinical use.